Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

abstract：PURPOSE:Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian ca...

journal_title：Cancer chemotherapy and pharmacology

authors： Pisano C,Morabito A,Sorio R,Breda E,Lauria R,Gebbia V,Scaltriti L,Scalone S,Zagonel V,Greggi S,Beneduce G,Losito S,Gallo C,Di Maio M,Forestieri V,Pignata S

更新日期：2009-10-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs. METHODS:The antitumor activity of fourteen anticancer drugs was tested in over one hundred tumor samples from pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Haglund C,Aleskog A,Nygren P,Gullbo J,Höglund M,Wickström M,Larsson R,Lindhagen E

更新日期：2012-03-01 00:00:00

abstract：:The present paper reviews several studies performed between 1977 and 1986 in Singapore on the 10-year survival outcome of treatment for stage I and II hepatocellular carcinoma (HCC). Of 801 HCC patients evaluated, only 2 survivors (0.3%) remained in complete remission for 13 and 14 years, respectively. One had receive...

journal_title：Cancer chemotherapy and pharmacology

authors： Oon CJ

更新日期：1992-01-01 00:00:00

abstract：:The cytotoxicity of 5-fluorouracil (5-FU) is due in part to the incorporation of the base into RNA molecules. We assessed the cytotoxicity of 5-FU in human colonic carcinoma HT-29 cells and examined mRNA activity (measured by protein biosynthesis in vivo and in vitro) and the maturation of rRNA precursors as two possi...

journal_title：Cancer chemotherapy and pharmacology

authors： Greenhalgh DA,Parish JH

更新日期：1989-01-01 00:00:00

abstract：:Between December 1982 and November 1990, 31 patients with advanced urothelial carcinoma were treated with one of two combination chemotherapy regimens. A total of 20 patients were treated with 3 mg/m2 mitomycin C and 300 mg/m2 cyclophosphamide given intravenously every 10-14 days and with 180 mg/m2 5-fluorouracil (5-F...

journal_title：Cancer chemotherapy and pharmacology

authors： Sahashi M,Ono Y,Matsuura O,Ohshima S,Fukushima M

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

journal_title：Cancer chemotherapy and pharmacology

authors： Hurtubise A,Momparler RL

更新日期：2006-11-01 00:00:00

abstract：BACKGROUND:The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). METHODS:Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN;...

journal_title：Cancer chemotherapy and pharmacology

authors： Cho BC,Keum KC,Shin SJ,Choi HJ,Lee YJ,Kim SH,Choi EC,Kim JH

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:The combination of capecitabine and paclitaxel (XP) has demonstrated synergistic antitumor activity in preclinical models. The purpose of this phase II study was to evaluate the efficacy and safety of a monthly XP regimen in patients with metastatic breast cancer (MBC). METHODS:Eligible patients had received o...

journal_title：Cancer chemotherapy and pharmacology

authors： Taguchi T,Yamamoto D,Masuda N,Oba K,Nakayama T,Nagata T,Nomura M,Yoshidome K,Yoshino H,Matsunami N,Miyashita M,Furuya Y,Ishida T,Wakita K,Sakamoto J,Noguchi S,Kinki Breast Cancer Study Group (KBCSG).

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:To evaluate the effect of front-line chemotherapy on CK-19mRNA+ circulating tumor cells (CTCs) and their relevance in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS:The presence of CK-19mRNA+ CTCs was assessed using a real-time RT-PCR assay in 298 previously untreated patients with MBC befo...

journal_title：Cancer chemotherapy and pharmacology

authors： Georgoulias V,Apostolaki S,Bozionelou V,Politaki E,Perraki M,Georgoulia N,Kalbakis K,Kotsakis A,Xyrafas A,Agelaki S,Mavroudis D

更新日期：2014-12-01 00:00:00

abstract：:NQO1 is a reductive enzyme that is important for the activation of many bioreductive agents and is a target for an enzyme-directed approach to cancer therapy. It can be selectively induced in many tumor types by a number of compounds including dimethyl fumarate and sulforaphane. Mitomycin C is a bioreductive agent tha...

journal_title：Cancer chemotherapy and pharmacology

authors： Digby T,Leith MK,Thliveris JA,Begleiter A

更新日期：2005-09-01 00:00:00

abstract：PURPOSE:Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme important in DNA repair. PARP-1 activation at points of DNA strand break results in poly(ADP-ribose) polymer formation, opening the DNA structure, and allowing access of other repair enzymes. CEP-9722 inhibits PARP-1 and PARP-2 and is designed to potent...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Stephens P,Aissat-Daudigny L,Cambois A,Moachon G,Brown PD,Campone M

更新日期：2014-08-01 00:00:00

abstract：:The purpose of this study was to evaluate the response rate, methotrexate plasma levels, and toxicity of a three-drug regimen in patients with gastric carcinoma. A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF). Adriamyci...

journal_title：Cancer chemotherapy and pharmacology

authors： Ajani JA,Goudeau P,Levin B,Faintuch JS,Abbruzzese JL,Boman BM,Kanojia MD

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The interindividual variability of vincristine pharmacokinetics is quite large, but the origins of this variability are not properly understood. The aim of this study was to develop a population pharmacokinetic model of vincristine in a paediatric population treated for solid tumour disease and evaluate the imp...

journal_title：Cancer chemotherapy and pharmacology

authors： Guilhaumou R,Simon N,Quaranta S,Verschuur A,Lacarelle B,Andre N,Solas C

更新日期：2011-11-01 00:00:00

abstract：:Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol i...

journal_title：Cancer chemotherapy and pharmacology

authors： Gangemi RM,Tiso M,Marchetti C,Severi AB,Fabbi M

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To review the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma. PATIENTS AND METHODS:A total of 178 patients with inflammatory breast carcinoma were treated in the past 20 years at M. D. Anderson Cancer Center by a combined-modality ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno NT,Buzdar AU,Singletary SE,Ames FC,McNeese MD,Holmes FA,Theriault RL,Strom EA,Wasaff BJ,Asmar L,Frye D,Hortobagyi GN

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND:Metastatic bladder cancer is a serious condition with a 5-year survival rate of approximately 14 %, a rate that has remained unchanged for almost three decades. Thus, there is a profound need to identify the driving mutations for these aggressive tumors to better determine appropriate treatments. Mutational ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cirone P,Andresen CJ,Eswaraka JR,Lappin PB,Bagi CM

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC). Although bevacizumab i...

journal_title：Cancer chemotherapy and pharmacology

authors： Ortega J,Hayes JM,Antonia S

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS:Patients who failed prior standard therapy o...

journal_title：Cancer chemotherapy and pharmacology

authors： Holen KD,Belani CP,Wilding G,Ramalingam S,Volkman JL,Ramanathan RK,Vasist LS,Bowen CJ,Hodge JP,Dar MM,Ho PT

更新日期：2011-02-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：:The antimetabolite 1-beta-D-arabinofuranosyl-cytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this...

journal_title：Cancer chemotherapy and pharmacology

authors： Wills P,Hickey R,Ross D,Cuddy D,Malkas L

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:In the treatment of head and neck malignancy, cisplatin and 5-FU have been used the most as chemotherapeutic agents. The difference in efficacies of these is unclear and controversial. To investigate more effective schedule, we analyzed the cytotoxicity in different treatment sequence with two agents in vitro a...

journal_title：Cancer chemotherapy and pharmacology

authors： Ijichi K,Adachi M,Hasegawa Y,Ogawa T,Nakamura H,Kudoh A,Yasui Y,Murakami S,Ishizaki K

更新日期：2008-10-01 00:00:00

abstract：:Reduced drug accumulation may be one reason for intrinsic drug resistance in chronic lymphatic leukemia of the B-cell type (B-CLL). Immunophenotyped leukemic human B-cells from 38 cases of B-CLL were characterized for P-glycoprotein (PGP) content. In all, 30 cases of B-CLL were additionally analyzed for further parame...

journal_title：Cancer chemotherapy and pharmacology

authors： Reichle A,Diddens H,Altmayr F,Rastetter J,Andreesen R

更新日期：1994-01-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:The majority of patients with low-grade non-Hodgkin's lymphoma (LGNHL) are in the older age groups and are thus less able to tolerate aggressive treatment. Chlorambucil, alone and in combination, has been widely accepted as the initial treatment of choice for many years. The availability of an anthracycline whi...

journal_title：Cancer chemotherapy and pharmacology

authors： Taylor PR,Jackson GH,Galloway MJ,Soukop M,Tinegate H,Angus B,Proctor SJ

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:To investigate whether coadministration of vindesine is a risk factor for acute kidney injury caused by high-dose methotrexate in patients with hematologic malignancies and identify its mechanism. METHODS:A retrospective analysis was conducted on 211 cycles of HD-MTX therapy in 178 patients with hematological ...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Xia F,Xue L,Liu L,Bian Y,Jin Z,Miao L

更新日期：2020-02-01 00:00:00

abstract：:New 4'-C-methyl analogues of daunorubicin, synthesized by the coupling reaction of daunomycinone with 1-chloroderivatives of protected 4-C-methyldaunosamine analogues, were chemically transformed to the corresponding doxorubicin analogues. Their cytotoxic effect against HeLa cells, ability to bind to DNA, and in vivo ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bargiotti A,Casazza AM,Cassinelli G,Di Marco A,Penco S,Pratesi G,Supino R,Zaccara A,Zunino F,Arcamone F

更新日期：1983-01-01 00:00:00

abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

journal_title：Cancer chemotherapy and pharmacology

authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

journal_title：Cancer chemotherapy and pharmacology

authors： Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. METHODS:We examined the relation of morphine-related adverse events to polymorphisms in UDP-glucuronosyltransferase (UGT) 2B7, ATP-binding cassette, sub-family B, number 1 (ABCB1), and μ-opioid receptor 1...

journal_title：Cancer chemotherapy and pharmacology

authors： Fujita K,Ando Y,Yamamoto W,Miya T,Endo H,Sunakawa Y,Araki K,Kodama K,Nagashima F,Ichikawa W,Narabayashi M,Akiyama Y,Kawara K,Shiomi M,Ogata H,Iwasa H,Okazaki Y,Hirose T,Sasaki Y

更新日期：2010-01-01 00:00:00

abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

journal_title：Cancer chemotherapy and pharmacology

authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

更新日期：2019-03-01 00:00:00